ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Institut Pasteur and Sinovac Biotech side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Institut PasteurSinovac Biotech
studies on the registry99163
open to participants now4136
phase 3 studies under way117
reach primary completion within a year1315
programswith a study of their own in two years132

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseInstitut PasteurSinovac Biotech
Phase 1

Institut Pasteur: 1 of its 1 programs at phase 1

  1. Low dose MOPEVAC-Las vaccinephase 1
100%
13%
Phase 200%28%
Phase 300%34%
Approved, new studies00%

Sinovac Biotech: 8 of its 32 programs at approved, new studies

  1. experimental vaccineapproved, new study
  2. Chickenpox Vaccineapproved, new study
  3. EV71approved, new study
  4. Poliovirus Vaccine, Inactivatedapproved, new study
  5. 1wIPV+2sIPVapproved, new study

and 3 more — sign in to see them all

25%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Institut Pasteur0 readouts · 0 phase 3············
Sinovac Biotech9 readouts · 7 phase 3

Sinovac Biotech, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. experimental vaccineapproved, new study · Nov 0 · NCT07505888

Sinovac Biotech, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Cell-based Trivalent Split Influenza Virus Vaccine (cTIV)phase 1 · Dec 0 · NCT07889193
  2. Rabies Vaccine (Serum-free Vero Cell), Freeze-driedphase 3 · Dec 30 · NCT07055295

Sinovac Biotech, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. EV71approved, new study · Jan 9 · NCT07793175
  2. Rabies vaccinephase 3 · Jan 30 · NCT07055893

Sinovac Biotech, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Anflu®approved, new study · Feb 0 · NCT07832201

Sinovac Biotech, Mar ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Sinovac PCV13phase 3 · Mar 0 · NCT07832500
  2. SNA02-48phase 3 · Mar 31 · NCT07633119
·····

Sinovac Biotech, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)phase 3 · Sep 15 · NCT07793227
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Institut Pasteur

New programs 1

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Sinovac Biotech

New programs 3

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

No condition where two of them both have programs.

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Institut Pasteur 1 of 1 · Sinovac Biotech 21 of 32 programs. Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.